AzTrials
AzTrials

Peripheral Arterial DiseaseNCT05619835

A Usability Study of a Tele-health Service for Patients With Peripheral Arterial Disease.

An observational study of Peripheral Arterial Disease, run by Medical University of Graz at 1 site in Austria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the study is to analyze the applicability (usability) of a tele-health service as part of a potential disease management program for patients with peripheral arterial disease. The following investigations will be conducted as part of the usability study. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Peripheral Arterial Disease
How many people
20 participants
Where
1 siteAustria
Study dates
11 Nov 2022to 30 Aug 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients diagnosed with IIa and IIb PAD at the Department of Angiology at the LKH-University Hospital Graz.

Who may be able to join

  • Documented diagnosis of "peripheral arterial occlusive disease" in, IIa and IIb (according to Fontaine).
  • Age between 18 and 80 years
  • Written informed consent
  • Smartphone with Android operating system
  • Understanding of how to use the tele-health service

Who cannot join

  • Patients with PAD stages I, III and IV (according to Fontaine)
  • Lack of compliance
  • Smartphone with non-Android operating system or incompatible software

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Medical University of Graz

    Graz, Styria, 8036

Other trials in Austria

About this study

The aim of the study is to analyze the applicability (usability) of a tele-health service as part of a potential disease management program for patients with peripheral arterial disease.

The following investigations will be conducted as part of the usability study. In the context of a tele-health service, knowledge, physical condition (including walking distance) will be documented during face-to-face and televisits, dislocated supervised gait training and education will be provided, and satisfaction with the tele-health service will be evaluated.

Read the detailed description

Disease management programs (DMPs) are one of the methods used to optimize the care of patients with chronic diseases. DMPs are coordinated health care measures for patient populations with diseases in which active patient participation in treatment can lead to substantial effects. Specific treatment regimens, based on evidence-based treatment guidelines and structured patient information, are predominantly aimed at preventing disease exacerbations and complications. The World Health Organization (WHO) also recommends, among other things, forcing patient adherence through structured information and patient empowerment strategies to establish participatory treatment.

Peripheral arterial disease (PAD) causes oxygen and nutrient deprivation of tissues through narrowing of arterial vessels in the extremities. The cause of PAD is arteriosclerosis. The course of the disease begins asymptomatically and manifests itself over time with pain and cramps predominantly in the muscles of the lower extremity. The pain symptoms usually occur initially during physical exertion, and later at rest. As PAD progresses, chronic ulceration and necrosis occur.

Professional societies such as the European Society of Cardiology (ESC) and the European Society of Vascular Medicine (ESVM) regularly publish guidelines for the diagnosis and treatment of PAD. Therapy of PAD consists of drug therapy for the purpose of cardiovascular risk reduction (lipid and blood pressure lowering drugs and anticoagulant drugs as well as therapy of diabetes mellitus). Another aspect in the event of disease progression is interventional angioplasty, in which the affected constriction in the leg arteries is dilated and, if necessary, treated with stents. Another important pillar is also structured and supervised gait training and, in general, an improvement in lifestyle with cessation of nicotine abuse and a healthy diet.

In particular, structured gait training, which should be performed at least three times a week for 30 to 60 minutes, is strongly recommended in the current ESVM and ESV guidelines. Studies showed that structured gait training can increase walking distance by 200% in 12 weeks in patients with claudication. Daily individual interval training of 60 minutes with 5- to 15-minute intervals also proved effective in increasing walking distance. This is to overcome the pain threshold of claudication while walking. Furthermore, evidence showed that gait training may be equivalent to endovascular interventions in terms of long-term outcomes.

The aim of this study is to analyze the applicability (usability) of a telehealth service as part of a potential disease management program for patients with peripheral arterial disease.

A prospective monocentric pilot study will be conducted at the clinical department of angiology.

The study duration per participant is 90 (±14) days and is divided into 2 observation phases. In phase 1, there will be supervision by a certified nurse and the telehealth service app, and in phase 2, there will be only singular use of the app without contact by the certified nurse.

The Declaration of Helsinki (as amended from time to time) and the guidelines of "Good Clinical Practice" were taken into account in the conduct and also the planning of the study.

Furthermore, the framework guideline for the "IT infrastructure in the application of telemonitoring" was used for the planning of the study.

According to the manufacturer's manuals, the pedometers AS80/AS97/AS99 from the company Beurer are not medical devices. The app serves as a diary for patients and is not a Clinical Decision Support System. The "User's Manual PAD Stepping" is included with the study material.

Reference Projects:

The DMS app system is also already being used in routine care in the "Herzmobil" project in Styria and Tyrol. Here, patients with chronic heart failure are cared for.

The use of the DMS app is currently also being used in two other studies. These are observational studies that are not subject to the Medical Devices Act. Both projects have a positive ethics vote and are listed under the following titles:

  • Telemedical follow-up of hospitalized patients with coronavirus disease-2019 (COVID-19) DRKS ID of the study: DRKS00022244.
  • Building a training database of voice data recordings and body weight trajectories in hemodialysis patients for algorithm development.
Keywords
Peripheral Arterial Disease, Walking exercise, Tele-health Service, Disease Management Program, Preventive Medicine, Integrated care, Vascular Medicine
Medical subject headings
Peripheral Arterial Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Patient satisfaction with the telehealth service.

    Study participants will undergo guided interviews measuring patient satisfaction with telehealth service.

    Measured: At time point visit 3, which is 12 weeks after baseline

Secondary outcomes (8)
  1. Proportion of patients, who would be satisfied with the telehealth service if telephone calls would not be provided by a nurse during the programme

    Yes/No

    Measured: At time point visit 3, which is 12 weeks after baseline

  2. Change of walking distances in the 6 minute walk test determined by the certified nursing staff in response to the telehealth service.

    Walking distances in the 6 minute walk test will be determined by the certified nursing staff.

    Measured: From baseline to visit 3, which is 12 weeks after baseline

  3. Change of subjective limitations in the activities of daily living.

    Study participants will undergo a questionaire (SF36) measuring subjective limitations in the activities of daily living.

    Measured: From baseline to visit 3, which is 12 weeks after baseline

  4. Change of knowledge about peripheral arterial disease.

    Study participants will undergo a questionaire measuring knowledge about peripheral arterial disease before and 12 weeks after a structured education.

    Measured: From baseline to visit 3, which is 12 weeks after baseline

  5. Total number of performed 6 minute walk tests during the telehealth service.

    Study participants will perform 6 minute walk tests independently using the App during the telehealth service.

    Measured: At time point visit 3, which is 12 weeks after baseline

  6. Differences of the walking distance in the same 6 minute walk test determined by the nursing staff compared the App.

    Walking distances in the 6 minute walk test will be determined by the certified nursing staff as well as by the App.

    Measured: At baseline and at visit 3, which is 12 weeks after baseline

  7. Average steps per day during the telehealth service.

    Descriptive

    Measured: From baseline to visit 3, which is 12 weeks after baseline

  8. Change of summed seconds in the "Time up and Go Test".

    The "Time up and Go Test" will be performed by an installed automatic measure system and will be observed by the certified nursing staff. The patient has to stand up from a chair and walk three meter straight. The time needed for this procedure will be measured exactly by a sensor supported measure system.

    Measured: From baseline to visit 3, which is 12 weeks after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Nov 2022
  2. Study start11 Nov 2022
  3. Primary completion30 Aug 2023
  4. Study completion30 Aug 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05619835
Sponsor's protocol ID
1566-2021
Status last verified
Oct 2023
First submitted
7 May 2022
Last updated
1 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Peripheral Arterial Disease, run by Medical University of Graz at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Patient satisfaction with the telehealth service. (time frame: At time point visit 3, which is 12 weeks after baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in